In lung cancer, immunization with a Ddx21 mutant peptide (Ddx21^MT) generated durable anti-tumor immunity and increased central memory (T_CM) CD8+ T cells in mice, explaining the superior protection previously seen with an early-lesion–derived vaccine (144). Here, CD8A is linked to neoplasm.